Brought to you by 
AZ grants Insmed exclusive global rights to pulmonary disease compound
06 Oct 2016
Executive Summary
AstraZeneca PLC granted Insmed Inc. exclusive global rights to the dipeptidyl peptidase 1 inhibitor AZD7986, which Insmed will rename INS1007 and develop for non-cystic fibrosis bronchiectasis.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
- Reverse Licensing
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
AZ grants Insmed exclusive global rights to pulmonary disease compound
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice